Pediatrics | Eklavya Medical

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 201 person Asked by .

bookmark_add

Acute Liver Failure (ALF) in Children

description Clinical Response

Q158 ★ · DNB/MD 2023/2

Acute Liver Failure (ALF) in Children

Examiner's Intent: Pediatric ALF is a time-critical, multi-system emergency; examiners expect the specific PALF diagnostic criteria, a systematic etiological approach, and clear understanding of cerebral edema monitoring/management, extending the general ICP framework in Section 2.

PALF Study Group Criteria

Requires biochemical evidence of acute liver injury (no known chronic liver disease) plus coagulopathy not correctable by vitamin K:

Criterion	Encephalopathy Requirement
INR ≥ 1.5	Clinical hepatic encephalopathy must be present
INR ≥ 2.0	Encephalopathy not required (present or absent)

Note: Encephalopathy is not an absolute prerequisite if coagulopathy is severe enough (INR ≥2.0) — important since young children can be difficult to reliably assess for subtle early encephalopathy.

Etiological Workup — A Systematic, Age-Stratified Approach

Category	Examples
Infectious	Viral hepatitis (A, B, E); HSV hepatitis (especially neonates/young infants — specifically aciclovir-responsive)
Metabolic	Galactosemia, tyrosinemia, mitochondrial disorders, Wilson disease (low alk phos relative to bilirubin + Coombs-negative hemolytic anemia) — often leading category in neonates/young infants
Toxic	Paracetamol overdose (Rumack-Matthew nomogram), other hepatotoxic drugs
Autoimmune	Autoimmune hepatitis presenting as fulminant failure in a subset
Indeterminate	Substantial proportion remain without identified cause

Monitoring for Hepatic Encephalopathy and Cerebral Edema

Serial neurological assessment is essential, extending the general raised ICP framework (Section 2, Q29):

Head elevation
Avoidance of hypercapnia/hypoxemia
Careful, individualized fluid management
Hyperosmolar therapy (hypertonic saline or mannitol) for evolving edema
Invasive ICP monitoring considered only in the most severe cases at specialized centers — ALF coagulopathy substantially raises bleeding risk of monitor placement

Liver Transplantation Criteria

Prognostic scoring incorporates coagulopathy severity/trend, encephalopathy grade, and etiology (major prognostic weight):

Etiology	Prognosis
Wilson disease-associated ALF	Generally poor spontaneous recovery — earlier, proactive transplant listing
Indeterminate etiology	Generally poor prognosis
Paracetamol-induced (early NAC treatment)	Comparatively more favorable spontaneous recovery potential

Note: Timing of transplant listing is one of the most critical, time-pressured judgments in pediatric hepatology — the window closes either with spontaneous recovery or with deterioration beyond benefit from transplant.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 202 person Asked by .

bookmark_add

Extrahepatic Biliary Atresia (EHBA)

description Clinical Response

Q159 ★ · DNB/MD 2023/1

Extrahepatic Biliary Atresia (EHBA)

Examiner's Intent: EHBA is perhaps the single most time-critical diagnosis in pediatric hepatology, given the sharply age-dependent success of the Kasai procedure; examiners expect articulation of why timing is critical, the stool color card screening tool, and the diagnostic protocol.

Pathophysiology

Progressive, postnatal fibro-obliteration of the extrahepatic (and variably intrahepatic) bile ducts → complete biliary obstruction. Proposed trigger: aberrant perinatal viral infection triggering autoimmune-mediated bile duct injury (not conclusively established).

Note: EHBA is a progressive postnatal process, not a static congenital malformation — injury worsens with increasing age at surgery, directly underlying the urgency of early diagnosis/treatment.

Stool Color Card Screening

Parents compare infant stool color (normal yellow/green vs pale/acholic white/clay-colored) against a reference card during the first weeks of life. Persistently pale stool prompts urgent evaluation. Successfully implemented at national/regional level (notably Taiwan), reducing age at diagnosis and improving Kasai outcomes population-wide.

[Diagram: Stool color reference card: gradient from normal yellow/green stools to pale/acholic white/clay-colored stools]

Diagnostic Protocol

Investigation	Key Finding
Abdominal ultrasound	“Triangular cord sign” at porta hepatis; absent/atretic/non-contractile gallbladder; excludes choledochal cyst
HIDA scan (after phenobarbital pretreatment)	Absent radiotracer excretion into intestine despite adequate hepatic uptake — not fully specific to EHBA alone
Liver biopsy	Bile duct proliferation, portal fibrosis, bile plugs — distinguishes EHBA from other neonatal cholestasis causes
Intraoperative cholangiography	Definitive diagnostic confirmation, performed at surgical exploration

Kasai Portoenterostomy — Timing and Outcomes

Excision of the fibrotic extrahepatic biliary remnant at the porta hepatis, with a Roux-en-Y jejunal loop anastomosed to the exposed hepatic surface for bile drainage.

Critical: Success rates decline progressively and often dramatically when surgery is performed beyond approximately 45–60 days of age — timing is the single most critical determinant of success.

Post-Kasai Management

Prophylactic antibiotics (risk of ascending cholangitis via the biliary-enteric connection)
Choleretic therapy (ursodeoxycholic acid)
Fat-soluble vitamin supplementation
Nutritional optimization

Kasai is a valuable bridging intervention that can delay (and sometimes avoid) transplantation — not uniformly curative; many progress to fibrosis/cirrhosis and eventually require transplant.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 203 person Asked by .

bookmark_add

Asthma Guidelines (GINA 2023/2024)

description Clinical Response

Q160 · DNB/MD 2022/2

Asthma Guidelines (GINA 2023/2024)

Examiner's Intent: Expects awareness of the age-stratified GINA stepwise framework and, importantly, the significant recent shift toward ICS-formoterol as a reliever (rather than SABA-only), a genuinely important recent guideline evolution.

Age-Stratified Stepwise Management

GINA provides distinct algorithms for children <5 years (greater diagnostic uncertainty, more empirical/trial-based treatment) and 6–11 years (more closely parallels, though remains distinct from, adult principles). Treatment is escalated/de-escalated per the “assess, adjust, review” cycle.

The Shift to ICS-Formoterol as Reliever — Track 1 vs Track 2

Track	Approach	Rationale
Track 1 (preferred)	Low-dose ICS-formoterol as reliever (replacing SABA alone)	Reduces severe exacerbation risk vs SABA-only; formoterol gives immediate bronchodilation, ICS component gives self-titrating, need-based anti-inflammatory increase precisely when symptoms worsen
Track 2 (alternative)	Traditional SABA reliever + separate regular maintenance ICS (or ICS-LABA)	Retained where ICS-formoterol reliever formulations are unavailable/unaffordable/not preferred

Note: SABA-only reliever therapy provides symptomatic relief without correspondingly increasing anti-inflammatory treatment during worsening symptoms — the key limitation Track 1 addresses.

Assessment of Asthma Control

GINA assesses: daytime symptom frequency, nighttime awakening, reliever use frequency, and activity limitation — categorized as well-controlled, partly controlled, or uncontrolled, combined with exacerbation history and future-risk factors, to guide stepwise adjustment at each review.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 204 person Asked by .

bookmark_add

Inflammatory Bowel Disease (IBD: Crohn's vs UC)

description Clinical Response

Q161 · DNB/MD 2022/1

Inflammatory Bowel Disease (IBD: Crohn’s vs UC)

Examiner's Intent: Expects clear clinical/endoscopic/histological differentiation between the two major IBD subtypes, and awareness of the evolving step-up versus top-down therapeutic strategy debate, particularly relevant to pediatric-onset disease.

Clinical Presentation

Feature	Crohn’s Disease	Ulcerative Colitis
Extent	Any GI segment, mouth to anus; transmural	Colon only, confined to mucosa
Pattern	“Skip lesions” — discontinuous, patchy	Continuous, from rectum extending proximally
Symptoms	Abdominal pain, diarrhea (often non-bloody), weight loss, growth failure (may be the presenting feature)	Bloody diarrhea, tenesmus, abdominal pain
Distinctive features	Perianal disease (fistulae, abscesses, skin tags), strictures, fistulas	Generally lacks growth failure prominence, perianal disease, fistulization

Endoscopic and Histological Differentiation

	Crohn’s Disease	Ulcerative Colitis
Endoscopy	Patchy/discontinuous, deep linear/“cobblestone” ulceration; terminal ileum involvement characteristic; rectal sparing possible	Continuous, confluent, always involves rectum; superficial ulceration, granular/friable mucosa
Histology	Transmural inflammation; non-caseating granulomas in a subset (relatively specific when present)	Mucosal/submucosal inflammation; crypt architectural distortion, crypt abscesses; no transmural extension/granulomas

[Diagram: Side-by-side schematic: Crohn's disease skip lesions/transmural inflammation vs UC continuous mucosal inflammation from rectum]

Therapeutic Strategies — Step-Up versus Top-Down

Strategy	Approach
Step-up (traditional)	5-ASAs → corticosteroids (induction) → conventional immunomodulators (azathioprine/methotrexate) → biologics (infliximab) only if inadequate
Top-down	Earlier biologic therapy (infliximab) in appropriately selected higher-risk patients — aims for rapid control and altering disease trajectory before irreversible damage (strictures, fistulae)

Note: Pediatric IBD, particularly Crohn’s, often follows a more aggressive course than adult-onset disease — contemporary management increasingly favors earlier, risk-stratified biologic use, also minimizing cumulative corticosteroid exposure given its adverse impact on growth.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 205 person Asked by .

bookmark_add

Acute Viral Bronchiolitis

description Clinical Response

Q162 · DNB/MD 2021/2

Acute Viral Bronchiolitis

Examiner's Intent: Expects clear understanding of the current evidence-based, deliberately minimalist supportive care approach, specific HFNC indications, and precise palivizumab prophylaxis eligibility criteria.

Etiology and Clinical Features

Most common lower respiratory tract infection in infants, predominantly caused by RSV (also rhinovirus, parainfluenza, human metapneumovirus). Coryzal prodrome → wheeze, crackles, tachypnea, increased work of breathing — typically <2 years, peak severity <6 months.

Evidence Against Bronchodilators and Steroids

Evidence-Based De-implementation: Current evidence-based guidelines (including AAP) do NOT recommend routine bronchodilators (salbutamol) or systemic/inhaled corticosteroids for typical bronchiolitis — robust trials/meta-analyses show no consistent clinical benefit. This contrasts deliberately with asthma management (Q160), reflecting bronchiolitis’s different pathophysiology (viral inflammation/mucus plugging/epithelial sloughing, not bronchospasm-predominant).

Supportive Care

Supplemental oxygen for hypoxemia
Nasal suctioning (infants are obligate/predominant nasal breathers)
Maintaining adequate hydration (NG or IV support if oral intake inadequate)

High-Flow Nasal Cannula (HFNC) Indications

Heated, humidified oxygen at flow rates exceeding standard low-flow — provides some positive airway pressure, improved secretion clearance, reduced work of breathing. Indicated for significant respiratory distress/hypoxemia not adequately managed with standard low-flow oxygen; an intermediate step before CPAP/mechanical ventilation.

Palivizumab Prophylaxis Criteria

High-Risk Group	Rationale
Significantly preterm infants (specific GA thresholds)	Elevated risk of severe RSV morbidity/mortality
Chronic lung disease of prematurity/BPD requiring ongoing support	Cross-referenced with Section 1, Q9
Hemodynamically significant congenital heart disease	—

Note: Nirsevimab, a newer longer-acting RSV monoclonal antibody, offers single-dose, whole-season protection (vs palivizumab’s monthly dosing) and, in some jurisdictions, is extended to broader infant populations — an actively-evolving “recent advances” area.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 206 person Asked by .

bookmark_add

Portal Hypertension & Variceal Bleeding

description Clinical Response

Q163 · DNB/MD 2021/1

Portal Hypertension & Variceal Bleeding

Examiner's Intent: Expects clear etiological distinction between the two major pediatric portal hypertension categories (a critical distinction given different management implications), and appropriate acute variceal bleeding management.

Etiology — EHPVO versus Cirrhosis

Category	Mechanism	Hepatic Function	Prognosis/Surgical Options
EHPVO (Extrahepatic Portal Vein Thrombosis/Obstruction)	Thrombotic obstruction of extrahepatic portal vein (umbilical vein catheterization/sepsis history, or idiopathic)	Preserved synthetic liver function	Better long-term prognosis; candidate for curative Meso-Rex shunt
Cirrhosis-related	Portal HTN from established hepatic parenchymal disease/fibrosis (post-Kasai biliary atresia, metabolic liver disease, autoimmune hepatitis, etc.)	Impaired synthetic/parenchymal function	Less favorable prognosis given progressive hepatic disease

Emergency Management of Acute Variceal Bleed

Octreotide infusion — reduces splanchnic blood flow/portal pressure, started promptly on clinical suspicion
Endoscopic band ligation — preferred technique for actively bleeding/high-risk esophageal varices
Careful, judicious fluid/blood resuscitation — avoid over-transfusion (risk of exacerbating portal pressure and rebleeding)
Prophylactic antibiotics — elevated infection risk (spontaneous bacterial peritonitis) with variceal bleeding in chronic liver disease

Shunt Surgeries — Meso-Rex Shunt for EHPVO

Bypasses the obstructed extrahepatic portal vein by connecting the superior mesenteric vein (often via autologous jugular vein graft) to the intrahepatic left portal vein at the “Rex recessus.”

[Diagram: Meso-Rex shunt schematic: SMV → jugular vein graft → intrahepatic left portal vein (Rex recessus), restoring hepatopetal flow]

Note: Restores normal, physiological hepatopetal (toward-liver) flow — genuinely curative in EHPVO given normal underlying hepatic parenchyma, distinct from traditional portosystemic shunts that simply divert flow away from the liver (used in cirrhotic portal hypertension where Meso-Rex is not applicable).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 207 person Asked by .

bookmark_add

Gastroesophageal Reflux Disease (GERD)

description Clinical Response

Q164 · DNB/MD 2020/2

Gastroesophageal Reflux Disease (GERD)

Examiner's Intent: Expects the fundamental, clinically important distinction between physiological GER and pathological GERD, appropriate diagnostic approach, and a management philosophy emphasizing conservative measures before pharmacological escalation.

GER versus GERD — A Critical Clinical Distinction

	GER	GERD
Nature	Physiological, benign; normal LES immaturity + liquid diet	Reflux causing troublesome symptoms/complications
Presentation	Frequent “spitting up” without complications	Feeding refusal/aversion, faltering growth, irritability, respiratory complications (aspiration, chronic cough, aspiration pneumonia), esophagitis (feeding aversion, hematemesis, stricture)
Course	Improves spontaneously, typically by 12–18 months	Requires evaluation and management
Management	Reassurance and parental education only	Conservative measures ± pharmacotherapy

Note: The mere presence of visible regurgitation, however frequent, does not by itself constitute GERD requiring treatment — over-diagnosis/over-treatment of simple physiological GER is a recognized clinical pitfall.

Diagnostic Evaluation

Uncomplicated GER: diagnosis is clinical, based on history alone. Suspected GERD may warrant:

24-hour pH-impedance monitoring — quantifies both acidic and non-acidic reflux with symptom correlation (more comprehensive than pH monitoring alone)
Upper endoscopy — where esophagitis, stricture, or another structural complication is suspected

Lifestyle versus Pharmacological Interventions

First-line (conservative): positioning (balanced against safe-sleep/SIDS guidance mandating supine sleep), feeding modifications (smaller frequent feeds, thickened feeds), and, where cow’s milk protein allergy is suspected, a trial of hydrolyzed/amino-acid formula or maternal dietary elimination.

Note: PPI therapy is reserved for confirmed/strongly suspected GERD not responding to conservative measures — of limited/no benefit for simple uncomplicated GER, and carries recognized risks (increased infection risk, other long-term concerns) that argue against indiscriminate use.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 208 person Asked by .

bookmark_add

Chronic Liver Disease & Portal Hypertension Complications

description Clinical Response

Q165 · DNB/MD 2020/1

Chronic Liver Disease & Portal Hypertension Complications

Examiner's Intent: Expects a systematic approach to the major complications of established pediatric cirrhosis, directly building on and complementing the portal hypertension/variceal bleeding discussion in Q163.

Evaluation of Cirrhosis in Children

Assessment includes hepatic synthetic function (albumin, coagulation profile), evidence of portal hypertension (splenomegaly, varices, thrombocytopenia from hypersplenism), and nutritional status.

Complication	Mechanism	Management
Ascites	Portal HTN (↑ hydrostatic pressure) + hypoalbuminemia (↓ oncotic pressure)	Sodium restriction, diuretics (spironolactone ± loop diuretic); therapeutic paracentesis for tense/symptomatic ascites
Spontaneous Bacterial Peritonitis (SBP)	Bacterial translocation into ascitic fluid without contiguous source	Diagnostic paracentesis — elevated ascitic fluid ANC supports diagnosis; prompt empirical antibiotics
Hepatic Encephalopathy	Ammonia/gut-derived neurotoxin accumulation from impaired hepatic clearance	Identify/treat precipitants (infection, GI bleed, constipation, electrolyte disturbance); lactulose
Hepatorenal Syndrome	Severe splanchnic vasodilation → compensatory renal vasoconstriction → renal hypoperfusion (functional, not structural)	Volume assessment/optimization; splanchnic vasoconstrictor (terlipressin) + albumin; liver transplantation is the only definitive treatment

Note: Hepatorenal syndrome must be distinguished from pre-renal azotemia (which responds to volume expansion) — true HRS characteristically does not.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 209 person Asked by .

bookmark_add

Intussusception

description Clinical Response

Q166 · DNB/MD 2019/2

Intussusception

Examiner's Intent: Expects the classic clinical triad, characteristic ultrasound findings, and clear management algorithm progressing from non-operative reduction to surgical indications.

Classic Clinical Triad

Feature	Description
Colicky abdominal pain	Episodic, paroxysmal waves; child draws up legs during episodes, comfortable between episodes
Vomiting	—
“Currant jelly” stool	Blood + mucus, reflecting mucosal ischemia/venous congestion — a relatively late finding present in only a minority; absence does not exclude diagnosis

A palpable, sausage-shaped abdominal mass (typically right upper quadrant) may also be found.

Ultrasound Findings

View	Sign
Transverse	“Target”/“doughnut” sign — concentric hyper-/hypoechoic rings (telescoped bowel layers)
Longitudinal	“Pseudokidney”/“sandwich” sign

[Diagram: Ultrasound target/doughnut sign (transverse) and pseudokidney/sandwich sign (longitudinal) of intussusception]

Management — Reduction Protocols and Surgical Indications

Non-operative reduction is first-line for hemodynamically stable children without peritonitis/perforation:

Technique	Method
Pneumatic (air) reduction	Fluoroscopic-guided air insufflation via rectal catheter; success confirmed by free reflux of air into small bowel
Hydrostatic reduction	Controlled saline (or contrast) instillation, typically ultrasound-guided

Note: Both carry a small but recognized risk of bowel perforation — require controlled pressure and immediate surgical backup.

Surgical Indications

Signs of peritonitis or bowel perforation (absolute contraindication to non-operative reduction)
Hemodynamic instability/signs of bowel ischemia/necrosis
Failure of non-operative reduction attempts
Identification of a pathological lead point (particularly relevant in older children — e.g., Meckel’s diverticulum, lymphoma) — contrasted with idiopathic, lymphoid-hyperplasia-related intussusception typical of young infants/toddlers

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 210 person Asked by .

bookmark_add

Congenital Lobar Emphysema & Lung Malformations

description Clinical Response

Q167 · DNB/MD 2018/2

Congenital Lobar Emphysema & Lung Malformations

Examiner's Intent: Expects clear differentiation of the three major congenital lung malformations, with particular attention to pulmonary sequestration's distinctive systemic (rather than pulmonary) blood supply — a genuinely important, frequently-tested anatomical distinguishing point with direct surgical implications.

Congenital Pulmonary Airway Malformation (CPAM)

Spectrum of cystic and/or solid abnormal lung tissue from disorganized fetal airway branching. Classified by cyst size/histology (varying malignancy potential in specific subtypes). Often antenatal ultrasound finding; postnatal presentation ranges from asymptomatic to significant respiratory distress (compression, mediastinal shift).

Pulmonary Sequestration — The Critical, Distinguishing Systemic Blood Supply

Key Surgical Point: Pulmonary sequestration is NOT connected to the normal tracheobronchial tree and receives blood supply from an anomalous systemic artery (most commonly from the descending thoracic or abdominal aorta), rather than the pulmonary arterial circulation. This aberrant vessel must be specifically identified and ligated during resection — failure to control it risks catastrophic intraoperative hemorrhage.

Subtype	Pleural Covering	Typical Presentation
Intralobar	Within the normal visceral pleura of an otherwise normal lobe	Later presentation, recurrent infection (some indirect drainage pathway)
Extralobar	Own separate visceral pleural covering	Antenatal/early infancy identification; more associated with other congenital anomalies

[Diagram: Pulmonary sequestration diagram showing anomalous systemic feeding artery from descending thoracic aorta bypassing the normal pulmonary arterial supply]

Congenital Lobar Emphysema (CLE)

Check-valve mechanism → progressive air trapping → massive hyperinflation of an affected lobe (most commonly left upper lobe), from bronchial cartilage deficiency/malacia or external compression. Presents with progressive respiratory distress in early infancy; chest imaging shows marked hyperlucency with compression atelectasis of adjacent lung (distinguishing it radiologically from CPAM's mixed cystic/solid appearance).

Diagnosis and Surgical Management

Antenatal ultrasound ± fetal MRI for detailed characterization
Postnatal CT chest (with contrast/angiography specifically for suspected sequestration)
Surgical resection (typically lobectomy, or limited resection for well-localized sequestrations) — generally recommended even for asymptomatic lesions given infection risk and, for CPAM, small long-term malignancy potential

Acute Liver Failure (ALF) in Children

PALF Study Group Criteria

Etiological Workup — A Systematic, Age-Stratified Approach

Monitoring for Hepatic Encephalopathy and Cerebral Edema

Liver Transplantation Criteria

Extrahepatic Biliary Atresia (EHBA)

Pathophysiology

Stool Color Card Screening

Diagnostic Protocol

Kasai Portoenterostomy — Timing and Outcomes

Post-Kasai Management

Asthma Guidelines (GINA 2023/2024)

Age-Stratified Stepwise Management

The Shift to ICS-Formoterol as Reliever — Track 1 vs Track 2

Assessment of Asthma Control

Inflammatory Bowel Disease (IBD: Crohn's vs UC)

Clinical Presentation

Endoscopic and Histological Differentiation

Therapeutic Strategies — Step-Up versus Top-Down

Acute Viral Bronchiolitis

Etiology and Clinical Features

Evidence Against Bronchodilators and Steroids

Supportive Care

High-Flow Nasal Cannula (HFNC) Indications

Palivizumab Prophylaxis Criteria

Portal Hypertension & Variceal Bleeding

Etiology — EHPVO versus Cirrhosis

Emergency Management of Acute Variceal Bleed

Shunt Surgeries — Meso-Rex Shunt for EHPVO

Gastroesophageal Reflux Disease (GERD)

GER versus GERD — A Critical Clinical Distinction

Diagnostic Evaluation

Lifestyle versus Pharmacological Interventions

Chronic Liver Disease & Portal Hypertension Complications

Evaluation of Cirrhosis in Children

Intussusception

Classic Clinical Triad

Ultrasound Findings

Management — Reduction Protocols and Surgical Indications

Surgical Indications

Congenital Lobar Emphysema & Lung Malformations

Congenital Pulmonary Airway Malformation (CPAM)

Pulmonary Sequestration — The Critical, Distinguishing Systemic Blood Supply

Congenital Lobar Emphysema (CLE)

Diagnosis and Surgical Management

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews